molecular-biology-heart-congress-2018-posters

4 / 21

Page 28
Notes:
allied
academies
Journal of Biomedical Research | Volume: 29
November 19-20, 2018 | Paris, France
Molecular Biology, Tissue Science and Regenerative Medicine
International Conference on
Joint Event
&
4th World Heart Congress
To evaluate the effect of ellagic acid treatment on the cell viability of human prostate cancer cells
Arshi Malik
King Khalid University, Saudi Arabia
Objective: To evaluate the effect of ellagic acid treatment on
the cell viability of human prostate cancer cells.
Methods: Ellagic acid (10-100mol/L) treatment (48h) of human
prostate carcinoma PC3 cells was found to result in a dose-
dependent inhibition of cell growth and apoptosis of PC3 cells
as assessed byMTT assay, western blotting, flow cytometry and
confocal microscopy.
Results: We observed that ellagic acid treatment of PC3 cells
resulted in a dose dependent inhibition of cell growth/cell
viability. This ellagic acid caused cell growth inhibition was
found to be accompanied by induction of apoptosis, as assessed
by the cleavage of poly (ADP-ribose) polymerase (PARP) and
morphological changes. Further, induction of apoptosis
accompanied a decrease in the levels of antiapoptotic protein
Bcl-2 and increase in proapoptotic protein Bax, thus shifting
the Bax: Bcl-2 ratio in favor of apoptosis. Ellagic acid treatment
of PC3 cells was also found to result in significant activation
of caspases, as shown by the dose dependent decrease in the
protein expression of procaspase−3, −6, −8 and −9. This ellagic
acid-mediated induction of apoptosis was significantly (80%-
90%) inhibited by the caspase inhibitor N-benzyloxycarbonyl-
Val-Ala-Asp (OMe)-fluoromethylketone (Z-VAD-FMK). Thus,
these data suggested an essential role of caspases in ellagic
acid-mediated apoptosis of PC3 cells.
Conclusions: It is tempting to suggest that consumption of
tropical pigmented fruits and vegetables could be an effective
strategy to combat prostate cancer.
Speaker Biography
Arshi Malik is currently an assistant professor at the College of Medicine, Department of
Clinical Biochemistry, King Khalid University, Kingdom of Saudi Arabia. His work mainly
focusses on chemoprevention and chemotherapy by various natural agents. He has an
extensive experience with human tissue culture, orthotopic/ecotopic implantations of
tumors in rodents, tail vein injections, surgery of small animals. Before coming to King
Khalid University in Saudi Arabia, he also taught/mentored undergraduate students
at Harvard Medical School, Boston as well as at the University of Wisconsin, Madison,
United States. Arshi earned his PhD degree in Biochemistry in the year 2002 from
Aligarh University in India.
e:
Arshi Malik, Molecular Biology & Heart Congress 2018, Volume 29
DOI: 10.4066/biomedicalresearch-C8-023